Bisphosphonate-Linked TrkB Agonist: Cochlea-Targeted Delivery of a Neurotrophic Agent as a Strategy for the Treatment of Hearing Loss
作者:Judith S. Kempfle、Kim Nguyen、Christine Hamadani、Nicholas Koen、Albert S. Edge、Boris A. Kashemirov、David H. Jung、Charles E. McKenna
DOI:10.1021/acs.bioconjchem.8b00022
日期:2018.4.18
to the SGNs to promote survival, neurite outgrowth, and, potentially, regeneration of synapses between HCs and SGNs. The design and synthesis of a bisphosphonate conjugate of DHF (Ris-DHF) is presented, with a preliminary evaluation of its neurotrophic activity. Ris-DHF increases neurite outgrowth in vitro, maintains this ability after binding to hydroxyapatite, and regenerates synapses in kainic acid-damaged
听力损失影响超过三分之二的老年人口,在美国所有成年人中,超过17%的人与噪声暴露或衰老相关的感音神经性听力损失与内耳感觉毛细胞(HCs),耳蜗螺旋神经节的丧失有关神经元(SGNs)和HCs与SGNs之间的带状突触,激起了人们对重新产生突触功能的疗法的浓厚兴趣。7,8-二羟基黄酮(DHF)是原肌球蛋白受体激酶B(TrkB)的选择性强效激动剂,可保护神经元免于细胞凋亡。尽管有证据表明TrkB激动剂可以促进SGN的存活,但将DHF等药物向内耳局部递送仍然是一个挑战。我们先前在动物模型中证明了荧光标记的双膦酸酯6-FAM-Zol,给予圆窗膜的药物穿透膜并扩散到整个耳蜗。考虑到它们对包括耳蜗骨在内的骨矿物质的亲和力,双膦酸盐为将神经营养剂靶向递送至SGN提供了一种有趣的方式,从而促进了HC和SGN之间的存活,神经突增生以及可能的突触再生。介绍了DHF的双膦酸酯共轭物(Ris-DHF)的设计和合成,并